SUMMARY Data concerning circulating immune complexes were obtained for women who had had a pulmonary embolism, myocardial infarction, or cerebral thrombosis, and for 224 healthy controls. In women with pulmonary embolism who had used oral contraceptives concentrations of circulating immune complexes were significantly higher than in healthy controls (regardless of oral contraceptive use), or in those with pulmonary embolism who had never used these preparations. Concentrations of circulating immune complexes were not raised in myocardial infarction, but these women had major risk factors for ischaemic heart disease. The group of patients with cerebral thrombosis without risk factors tended to have high concentrations of circulating immune complexes.
SUMMARY Data concerning circulating immune complexes were obtained for women who had had a pulmonary embolism, myocardial infarction, or cerebral thrombosis, and for 224 healthy controls. In women with pulmonary embolism who had used oral contraceptives concentrations of circulating immune complexes were significantly higher than in healthy controls (regardless of oral contraceptive use), or in those with pulmonary embolism who had never used these preparations. Concentrations of circulating immune complexes were not raised in myocardial infarction, but these women had major risk factors for ischaemic heart disease. The group of patients with cerebral thrombosis without risk factors tended to have high concentrations of circulating immune complexes.
The data provide some confirmation that immunological mechanisms may play a role in thrombotic episodes associated with oral contraceptives, expecially when they occur in the absence of risk factors for vascular disease.
The association between oral contraceptives and thrombosis is now well established. Initial case reports have been confirmed by epidemiological studies, and users of oral contraceptives appear to be at an increased risk of venous thromboembolism,'-3 cerebral thrombosis,23 and myocardial infarction.2 4 5 Oral contraceptives are well known to be associated with abnormalities of lipid and carbohydrate metabolism, which are in turn associated with an increased risk of ischaemic heart disease. It has been shown that the use of oral contraceptives is associated with changes in the coagulation and fibrinolytic systems. 6 In addition, changes in the structure of the tion of rare events suggested that an immunological mechanism might play a role in thrombosis among oral contraceptive users.8 Further studies indicated that some oral contraceptive users developed circulating immune complexes that precipitate in 25% saturated ammonium sulphate and that may contain antiethinyloestradiol antibodies.9 10 Laboratory methods were subsequently developed to test samples of venous blood for circulating immune complexes and antiethinyloestradiol antibodies. " I The purpose of this collaborative study was to apply these laboratory methods to a large population of women, with and without thrombosis, who were users and non-users of oral contraceptives. As well as including these women, we also collected similar information and blood samples from 224 women without a history of thrombosis. These women were identified through general practitioners, family planning clinics, and the Oxford Regional Blood Transfusion Service, and came from the same health districts and in similar proportions to the 114 women with thrombotic disease. The controls were not selected randomly but chosen to include reasonable numbers of women who had a history of oral contraceptive use, both current users and ex-users, and women who had never used oral contraceptives. Thus our data cannot be used to provide evidence concerning the risk of cardiovascular disease associated with the use of oral contraceptive.
All blood samples were handled in a similar way, and each batch that was despatched to Paris could include aliquots from women in each group. The numbers were allocated randomly, and the laboratory tests were carried out without knowledge of the clinical details. PROTEIN Complete data were obtained on 114 women with and 224 women without thrombotic disease. These two groups were subdivided for analysis into women who were current, past, or never users of oral contraceptives, as shown in Table 2 . (For the study groups, current use is defined as use within the month preceding the thrombotic episode and for the controls as use at the time of blood collection.) The group of women wth thrombotic disease included 28 with myocardial infarction, six with cerebral artery thrombosis, and 80 with pulmonary embolism. All but three of the women with myocardial infarction had recognised risk factors for ischaemic heart disease, whereas none of the patients with stroke were known to have major cardiovascular risk factors-namely, hypertension, hyperlipidaemia, smoking, or diabetes.
The reproducibility of the measurements of the concentrations of circulating immune complexes was assessed by analysing two or three repeat samples at intervals on 11 women (seven with and four without thrombotic events) participating in the study. Except for a single high result in one patient, which was not confirmed on a repeat testing, the results showed consistency. The coefficient of variation was within that demonstrated for the method.
CONCENTRATIONS OF CIRCULATING IMMUNE COMPLEXES
The Figure shows the concentrations of circulating immune complexes plotted on a log scale for each subgroup (see Table 3 for data).
Healthy users and non-users Concentrations of circulating immune complexes tended to be higher in healthy ever users of oral contraceptives than in women who never used the prep- Type of oral contraceptive-Our analysis considered not only user status-that is, current, past, or neverbut also the duration of use and type of preparation. Interesting historical differences in types of preparations emerge owing to the fact that the women who had had thrombotic disease ceased to take oral contraceptives after their hospital admission; because of this far fewer study patients than healthy women had ever used preparations containing less than 50 ,ug oestrogen per day. Over three quarters of the healthy current oral contraceptive users had used these lower dose preparations compared with only one quarter of women with pulmonary embolism at diagnosis. Nevertheless, when the women were analysed in three subgroups-those who had a history of using oral contraceptives containing >50 ,ug, 50 ug, and <50 ,ug oestrogen-no consistent trend in concentrations of circulating immune complexes was found. The mean concentrations for all women included in the study were subdivided into three groups. When a similar analysis was carried out on the women with pulmonary embolism and the healthy women there was no evidence that oral contraceptives containing higher doses of oestrogen were more commonly associated with higher concentrations of circulating immune complexes. We did not attempt an analysis by specific preparation (the numbers would have been too small), but our data do not suggest that the dose of oestrogen is an important confounding variable.
Duration of oral contraceptive use-Comparison of Plowright, Adam, Thorogood, Beaumont, Beaumont, Mann duration of use indicated that the healthy women study is the tendency of women who had had a pultended to have taken oral contraceptives for slightly monary embolism and used the pill at some time to longer than the women with thrombotic disease, but have higher concentrations of circulating immune these differences were not significant. complexes than either healthy oral contraceptive users Time since thrombotic event-All groups of oral con-or women who had had the condition but never used traceptive users included current and past users. the preparations. Thrombotic patients defined as current users all
The small number of patients with cerebral thromstopped taking oral contraceptives at the time of diag-bosis tended to have high concentrations, but those nosis, so that they might not have taken the prepara--with myocardial infarction did not. At first appeartions for several years before the time of sampling. -ance the data appear not to be entirely consistent with Consequently it is conceivable that the concqntrations the earlier findings from Paris. In the earlier study of circulating immune complexes might have fallen high concentrations of circulating immune complexes since the time of stopping these preparations. This were found, regardless of the site of the thrombosis, would, however, have resulted in patients with in women using oral contraceptives.'0 The inconsisthrombosis having lower rather than higher concen-tency is, however, almost certainly explained by the trations than the healthy users. In fact, patients with difference in case selection. The first series of cases thrombosis defined as past and current users had studied in Paris were characterised by the absence of identical concentrations of circulating immune com-predisposing factors for vascular disease.'0 In the preplexes, and these were not related to the time since sent epidemiological study patients were unselected stopping oral contraceptives.
with regard to predisposing factors. All those with Days to sending sample-The concentrations of cir-myocardial infarction had cardiovascular risk factors culating immune complexes were considered accord-and did not appear to have raised concentrations of ing to the number of days between collecting the sam-circulating immune complexes. On the other hand, ple and it arriving in Paris. The time interval was not the stroke patients did not have risk factors and found to have any effect on the concentration. appeared to have higher concentrations, but numbers Myocardial infarction and stroke-There were no are too small to draw definitive conclusions. Having significant differences between the concentrations of excluded pulmonary embolus in association with circulating immune complexes in the women with pregnancy, surgery, and trauma, we were left with a myocardial infarction and their equivalent healthy group without known risk factors for the condition. controls. Of the 28 cases of myocardial infarction, all This explanation is supported by a current study of but one had concentrations <700 ,ug/ml. It may be unselected patients in Paris,'3 which has shown a patrelevant though that the great majority of these tern of concentrations of circulating immune comwomen (25) had other risk factors for ischaemic heart plexes similar to that observed in our study. disease. The number of patients with cerebral thromThe healthy oral contraceptive users in our study bosis is very small, but it is of interest that this group, appear to have higher concentrations of circulating who did not have other cardiovascular risk factors, immune complexes than similar women studied in had high concentrations of circulating immune com-France,'3 the difference being entirely due to the plexes.
higher concentrations in past users. The current users have an almost identical mean concentration to those Discussion studied in Paris, and we are unable to explain the relatively high concentrations in our series of past Our methodology makes the assumption that, in the users. This finding, together with the considerable women with cardiovascular disease, the concentra-overlap between various groups, makes it difficult to tions of circulating immune complexes after the event define from the present data a cut off point below are similar to those beforehand. None of these which concentrations of circulating immune compatients continued to take oral contraceptives after plexes might be considered as normal or above which diagnosis and thus could not have developed higher they might be considered as abnormal. concentrations of circulating immune complexes as a
The present data (derived from an unselected popuresult of continuing exposure. Although it is conceiv-lation in another country), however, do provide able that the event itself might have stimulated the confirmatory evidence for the suggestion that an production of circulating immune complexes, our immunological mechanism may play a role in thromdata provide evidence that this is not the case: women botic episodes associated with oral contraceptive use, who had suffered a thrombotic episode but who had especially in women in whom these occur in the not used oral contraceptives had concentrations of cir-absence of risk factors for vascular disease. culating immune complexes similar to those in the Refinement of laboratory procedures and prospective healthy group. The most stfiking finding from our studies will be necessary to assess whether it is poss-ible to define a cut off point and whether it would be of value to use measurements of circulating immune complexes as a screening test for vascular complications in oral contraceptive users. The present data are encouraging.
risk of oral contraceptives. 
Immunogenicity and the vascular

